GMAB: Genmab A/S - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Genmab A/S

NASDAQ:GMAB

SummaryFactSheetFinancial
Price
$27.04
Loss Chance
42.9%
6.50JITTA SCORE
7.49%Over Jitta Line
Jitta Ranking
Biotechnology
53 / 282
Health Care
218 / 717
United States
?
2,049 / 4,223
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
ADMA Biologics
NASDAQ:ADMA
5.32
$10.31
39.07%
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
1.83
$5.28
73.65%
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
1.83
$5.28
73.65%
BioCryst Pharmaceuticals
NASDAQ:BCRX
4.62
$9.20
68.84%
BioMarin Pharmaceutical
NASDAQ:BMRN
6.75
$55.46
9.17%
Jitta Factors
Growth Opportunity (38)
Recent Business Performance (65)
Financial Strength (89)
Return to Shareholders (58)
Competitive Advantage (81)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Share RepurchaseEvery Year
CapExVery Low
Interest Coverage RatioVery Good
Recent Business PerformanceEarning decline 67.57% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
6.50
7.49%
2.24
183.94%
3.07
432.53%
Biotechnology
5.32
39.07%
1.82
73.65%
1.82
73.65%
COMPANY DESCRIPTION
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
www.genmab.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.